Stock Market News3 weeks CHMP Gives Nod to Expanded Use of J&J’s Rybrevant & AZN’s Imfinzi Zacks
The CHMP recommends approval for JNJ’s subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca’s Imfinzi in limited-stage small-cell lung cancer.
XThe CHMP recommends approval for JNJ’s subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca’s Imfinzi in limited-stage small-cell lung cancer.
X